Enhancing dopaminergic signaling and histone acetylation promotes long-term rescue of deficient fear extinction

Translational Psychiatry

Volumn 6, Issue 12, 2016, Pages

  Whittle, N ^a,b   Maurer, V ^a   Murphy, C ^a   Rainer, J ^a   Bindreither, D ^a   Hauschild, M ^a   Scharinger, A ^a   Oberhauser, M ^a   Keil, T ^a   Brehm, C ^a   Valovka, T ^a   Striessnig, J ^a   Singewald, N ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ENTINOSTAT; LEVODOPA; BENZAMIDE DERIVATIVE; DOPAMINE; HISTONE ACETYLTRANSFERASE; PYRIDINE DERIVATIVE;

AMYGDALA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR THERAPY; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; EPIGENETICS; FEAR; GENE EXPRESSION; GENE REGULATORY NETWORK; HISTONE ACETYLATION; LEARNING; MALE; MEDIAL PREFRONTAL CORTEX; MEMORY CONSOLIDATION; MOUSE; NERVE CELL; NONHUMAN; PROMOTER REGION; ANIMAL; CONDITIONED REFLEX; DRUG EFFECTS; IMPLOSIVE THERAPY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PREFRONTAL CORTEX; REINFORCEMENT; SIGNAL TRANSDUCTION;

AMYGDALA; ANIMALS; BENZAMIDES; COMBINED MODALITY THERAPY; CONDITIONING, CLASSICAL; DOPAMINE; EXTINCTION, PSYCHOLOGICAL; FEAR; HISTONE ACETYLTRANSFERASES; IMPLOSIVE THERAPY; LEVODOPA; MALE; MICE; PREFRONTAL CORTEX; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 85002778274     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.231     Document Type: Article

References (79)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
2. Kessler RC, Avenevoli S, McLaughlin KA, Green JG, Lakoma MD, Petukhova M et al. Lifetime co-morbidity of DSM-IV disorders in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A). Psychol Med 2012; 42: 1997-2010.
3. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655-679.
4. Cuijpers P. Effective therapies or effective mechanisms in treatment guidelines for depression? Depress Anxiety 2013; 30: 1055-1057.
5. Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015; 30: 183-192.
6. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psycho-pharmacol 2014; 28: 403-439.
7. Pull CB. Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders. Curr Opin Psychiatry 2007; 20: 30-35.
8. Doehrmann O, Ghosh SS, Polli FE, Reynolds GO, Horn F, Keshavan A et al. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry 2013; 70: 87-97.
9. Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 2011; 13: 423-437.
10. Chapman C, Mills K, Slade T, McFarlane AC, Bryant RA, Creamer M et al. Remission from post-traumatic stress disorder in the general population. Psychol Med 2012; 42: 1695-1703.
11. Boschen MJ, Neumann DL, Waters AM. Relapse of successfully treated anxiety and fear: theoretical issues and recommendations for clinical practice. Aust N Z J Psychiatry 2009; 43: 89-100.
12. Tovote P, Fadok JP, Luthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci 2015; 16: 317-331.
13. Bukalo O, Pinard CR, Holmes A. Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders. Br J Pharmacol 2014; 171: 4690-4718.
14. Whittle N, Singewald N. HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand? Biochem Soc Trans 2014; 42: 569-581.
15. Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther 2015; 149: 150-190.
16. Camp M, MacPherson KP, Lederle L, Graybeal C, Gaburro S, Debrouse LM et al. Genetic strain differences in learned fear inhibition associated with variation in neuroendocrine, autonomic, and amygdala dendritic phenotypes. Neuropsycho-pharmacology 2012; 37: 1534-1547.
17. Camp M, Norcross M, Whittle N, Feyder M, D'Hanis W, Yilmazer-Hanke D et al. Impaired Pavlovian fear extinction is a common phenotype across genetic lineages of the 129 inbred mouse strain. Genes Brain Behav 2009; 8: 744-752.
18. Fitzgerald PJ, Whittle N, Flynn SM, Graybeal C, Pinard CR, Gunduz-Cinar O et al. Prefrontal single-unit firing associated with deficient extinction in mice. Neurobiol Learn Mem 2014; 113: 69-81.
19. Gunduz-Cinar O, Macpherson KP, Cinar R, Gamble-George J, Sugden K, Williams B et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 2013; 7: 813-823.
20. Hefner K, Whittle N, Juhasz J, Norcross M, Karlsson RM, Saksida LM et al. Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain. J Neurosci 2008; 28: 8074-8085.
21. Macpherson K, Whittle N, Camp M, Gunduz-Cinar O, Singewald N, Holmes A. Temporal factors in the extinction of fear in inbred mouse strains differing in extinction efficacy. Biol Mood Anxiety Disord 2013; 3: 13.
22. Whittle N, Hauschild M, Lubec G, Holmes A, Singewald N. Rescue of impaired fear extinction and normalization of cortico-amygdala circuit dysfunction in a genetic mouse model by dietary zinc restriction. J Neurosci 2010; 30: 13586-13596.
23. Whittle N, Schmuckermair C, Gunduz Cinar O, Hauschild M, Ferraguti F, Holmes A et al. Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model. Neuro-pharmacology 2013; 64: 414-423.
24. Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol Rev 2009; 89: 121-145.
25. Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001; 294: 1030-1038.
26. Myers KM, Davis M. Behavioral and neural analysis of extinction. Neuron 2002; 36: 567-584.
27. Balooch SB, Neumann DL, Boschen MJ. Extinction treatment in multiple contexts attenuates ABC renewal in humans. Behav Res Ther 2012; 50: 604-609.
28. Reeves PG, Nielsen FH, Fahey GCJ. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993; 123: 1939-1951.
29. Sartori SB, Maurer V, Murphy C, Schmuckermair C, Muigg P, Neumann ID et al. Combined neuropeptide S and D-cycloserine augmentation prevents the return of fear in extinction-impaired rodents: advantage of dual versus single drug approaches. Int J Neuropsychopharmacol 2016; 19: pii: pyv128.
30. Quirk GJ, Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008; 33: 56-72.
31. Pape HC, Pare D. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev 2010; 90: 419-463.
32. Colombo PJ. Learning-induced activation of transcription factors among multiple memory systems. Neurobiol Learn Mem 2004; 82: 268-277.
33. Knapska E, Kaczmarek L. A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK? Prog Neurobiol 2004; 74: 183-211.
34. Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995; 16: 270-275.
35. Dayan L, Finberg JP. L-DOPA increases noradrenaline turnover in central and peripheral nervous systems. Neuropharmacology 2003; 45: 524-533.
36. Huebert ND, Palfreyman MG, Haegele KD. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3, 4-dihydrox-yphenylalanine. Drug Metab Dispos 1983; 11: 195-200.
37. Fornai F, Chen K, Giorgi FS, Gesi M, Alessandri MG, Shih JC. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study. J Neurochem 1999; 73: 2434-2440.
38. Morris MJ, Mahgoub M, Na ES, Pranav H, Monteggia LM. Loss of histone deace-tylase 2 improves working memory and accelerates extinction learning. J Neurosci 2013; 33: 6401-6411.
39. Fujita Y, Morinobu S, Takei S, Fuchikami M, Matsumoto T, Yamamoto S et al. Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. J Psychiatr Res 2012; 46: 635-643.
40. Matsumoto Y, Morinobu S, Yamamoto S, Matsumoto T, Takei S, Fujita Y et al. Vorinostat ameliorates impaired fear extinction possibly via the hippocampal NMDA-CaMKII pathway in an animal model of posttraumatic stress disorder. Psychopharmacology 2013; 229: 51-62.
41. Hait NC, Wise LE, Allegood JC, O'Brien M, Avni D, Reeves TM et al. Active, phos-phorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci 2014; 17: 971-980.
42. Lattal KM, Barrett RM, Wood MA. Systemic or intrahippocampal delivery of his-tone deacetylase inhibitors facilitates fear extinction. Behav Neurosci 2007; 121: 1125-1131.
43. Stafford JM, Raybuck JD, Ryabinin AE, Lattal KM. Increasing histone acetylation in the hippocampus-infralimbic network enhances fear extinction. Biol Psychiatry 2012; 72: 25-33.
44. Itzhak Y, Anderson KL, Kelley JB, Petkov M. Histone acetylation rescues contextual fear conditioning in nNOS KO mice and accelerates extinction of cued fear conditioning in wild type mice. Neurobiol Learn Mem 2012; 97: 409-417.
45. Bredy TW, Wu H, Crego C, Zellhoefer J, Sun YE, Barad M. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem 2007; 14: 268-276.
46. Bredy TW, Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn Mem 2008; 15: 39-45.
47. Graff J, Joseph NF, Horn ME, Samiei A, Meng J, Seo J et al. Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 2014; 156: 261-276.
48. Zhao Y, Zhong W, Sun X, Song Z, Clemens DL, Kang YJ et al. Zinc deprivation mediates alcohol-induced hepatocyte IL-8 analog expression in rodents via an epigenetic mechanism. Am J Pathol 2011; 179: 693-702.
49. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011; 29: 255-265.
50. Corcoran KA, Quirk GJ. Activity in prelimbic cortex is necessary for the expression of learned, but not innate, fears. J Neurosci 2007; 27: 840-844.
51. Burgos-Robles A, Vidal-Gonzalez I, Quirk GJ. Sustained conditioned responses in prelimbic prefrontal neurons are correlated with fear expression and extinction failure. J Neurosci 2009; 29: 8474-8482.
52. Sierra-Mercado D, Padilla-Coreano N, Quirk GJ. Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear. Neuropsychopharmacology 2011; 36: 529-538.
53. Vidal-Gonzalez I, Vidal-Gonzalez B, Rauch SL, Quirk GJ. Microstimulation reveals opposing influences of prelimbic and infralimbic cortex on the expression of conditioned fear. Learn Mem 2006; 13: 728-733.
54. Quirk GJ, Russo GK, Barron JL, Lebron K. The role of ventromedial prefrontal cortex in the recovery of extinguished fear. J Neurosci 2000; 20: 6225-6231.
55. Quirk GJ, Likhtik E, Pelletier JG, Pare D. Stimulation of medial prefrontal cortex decreases the responsiveness of central amygdala output neurons. J Neurosci 2003; 23: 8800-8807.
56. Herry C, Garcia R. Prefrontal cortex long-term potentiation, but not long-term depression, is associated with the maintenance of extinction of learned fear in mice. J Neurosci 2002; 22: 577-583.
57. Herry C, Mons N. Resistance to extinction is associated with impaired immediate early gene induction in medial prefrontal cortex and amygdala. Eur J Neurosci 2004; 20: 781-790.
58. Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 2002; 420: 70-74.
59. Barrett D, Shumake J, Jones D, Gonzalez-Lima F. Metabolic mapping of mouse brain activity after extinction of a conditioned emotional response. J Neurosci 2003; 23: 5740-5749.
60. Knapska E, Maren S. Reciprocal patterns of c-Fos expression in the medial pre-frontal cortex and amygdala after extinction and renewal of conditioned fear. Learn Mem 2009; 16: 486-493.
61. Herry C, Ciocchi S, Senn V, Demmou L, Muller C, Luthi A. Switching on and off fear by distinct neuronal circuits. Nature 2008; 454: 600-606.
62. Phelps EA, Delgado MR, Nearing KI, LeDoux JE. Extinction learning in humans: role of the amygdala and vmPFC. Neuron 2004; 43: 897-905.
63. Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL. Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biol Psychiatry 2007; 62: 446-454.
64. Milad MR, Pitman RK, Ellis CB, Gold AL, Shin LM, Lasko NB et al. Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol Psychiatry 2009; 66: 1075-1082.
65. Ji J, Maren S. Differential roles for hippocampal areas CA1 and CA3 in the contextual encoding and retrieval of extinguished fear. Learn Mem 2008; 15: 244-251.
66. Jin J, Maren S. Fear renewal preferentially activates ventral hippocampal neurons projecting to both amygdala and prefrontal cortex in rats. Sci Rep 2015; 5: 8388.
67. Hugues S, Garcia R, Lena I. Time course of extracellular catecholamine and glu-tamate levels in the rat medial prefrontal cortex during and after extinction of conditioned fear. Synapse 2007; 61: 933-937.
68. Hikind N, Maroun M. Microinfusion of the D1 receptor antagonist, SCH23390 into the IL but not the BLA impairs consolidation of extinction of auditory fear con-ditioning. Neurobiol Learn Mem 2008; 90: 217-222.
69. Mueller D, Bravo-Rivera C, Quirk GJ. Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses. Biol Psychiatry 2010; 68: 1055-1060.
70. Abraham AD, Neve KA, Lattal KM. Activation of D1/5 dopamine receptors: a common mechanism for enhancing extinction of fear and reward-seeking behaviors. Neuropsychopharmacology 2016; 41: 2072-2081.
71. Ponnusamy R, Nissim HA, Barad M. Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn Mem 2005; 12: 399-406.
72. Haaker J, Gaburro S, Sah A, Gartmann N, Lonsdorf TB, Meier K et al. Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear. Proc Natl Acad Sci USA 2013; 110: E2428-E2436.
73. Graff J, Tsai LH. The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol 2013; 53: 311-330.
74. Graff J, Tsai LH. Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci 2013; 14: 97-111.
75. Ferreira AN, Yousuf H, Dalton S, Sheets PL. Highly differentiated cellular and circuit properties of infralimbic pyramidal neurons projecting to the periaqueductal gray and amygdala. Front Cell Neurosci 2015; 9: 161.
76. Bukalo O, Pinard CR, Silverstein S, Brehm C, Hartley ND, Whittle N et al. Prefrontal inputs to the amygdala instruct fear extinction memory formation. Sci Adv 2015; 1: pii: e1500251.
77. Cho JH, Deisseroth K, Bolshakov VY. Synaptic encoding of fear extinction in mPFC-amygdala circuits. Neuron 2013; 80: 1491-1507.
78. Maroun M, Kavushansky A, Holmes A, Wellman C, Motanis H. Enhanced extinction of aversive memories by high-frequency stimulation of the rat infralimbic cortex. PLoS One 2012; 7: e35853.
79. Gazarini L, Stern CA, Piornedo RR, Takahashi RN, Bertoglio LJ. PTSD-like memory generated through enhanced noradrenergic activity is mitigated by a dual step pharmacological intervention targeting its reconsolidation. Int J Neuropsycho-pharmacol 2014, 18: pii: pyu026.